Variables | Univariable OR (95% CI), N = 544–571 | Univariable p | Multivariable OR (95% CI), N = 554 |
---|---|---|---|
Age, yrs | 1.01 (1.00–1.01) | 0.096 | ¥ |
Sex, female | 1.01 (0.81–1.25) | 0.963 | † |
Disease duration, yrs | 1.00 (0.99–1.02) | 0.528 | † |
Education, yrs | 0.97 (0.95–1.00) | 0.032 | ¥ |
No. comorbidities | 1.17 (1.08–1.26) | < 0.001 | 1.11 (1.03–1.20) |
Current smoker | 1.24 (1.01–1.53) | 0.041 | 1.26 (1.03–1.53) |
Type of center, academic | 0.82 (0.67–1.00) | 0.050 | 0.81 (0.68–0.98) |
RF positivity | 0.63 (0.51–0.77) | < 0.001 | * |
ACPA positivity | 0.57 (0.47–0.70) | < 0.001 | * |
RF and/or ACPA positivity | 0.58 (0.46–0.73) | < 0.001 | 0.66 (0.53–0.82) |
PtGA (0–10) ‡ | 1.11 (1.08–1.14) | < 0.001 | ¥ |
PGA (0–10) ‡ | 1.06 (1.03–1.10) | < 0.001 | ¥ |
Swollen joint count (0–44) ‡ | 1.00 (0.98–1.02) | 0.962 | † |
Tender joint count (0–53) ‡ | 1.03 (1.03–1.04) | < 0.001 | 1.02 (1.01–1.03) |
ESR, mm/h ‡ | 1.01 (1.00–1.01) | 0.013 | ¥ |
CRP, mg/l ‡ | 1.00 (0.99–1.00) | 0.453 | † |
HAQ ‡ | 1.43 (1.26–1.61) | < 0.001 | ¥ |
No. previous csDMARD | 1.02 (0.94–1.11) | 0.622 | † |
Previous treatment with any csDMARD | 1.10 (0.91–1.33) | 0.318 | † |
↵† Not selected from the univariable analysis (p > 0.20).
↵¥ Not significant in the multivariable analysis (p > 0.05).
↵‡ Modeled as time-varying.
↵* RF or ACPA positivity entered into multivariate model. Country added as a covariate in all univariable models and in the final multivariable model. Final model also adjusted for type of treatment (csDMARD and/or bDMARD). Values in bold face are statistically significant. T2T: treat-to-target; LDA: low disease activity; RA: rheumatoid arthritis; RF: rheumatoid factor; ACPA: anticitrullinated protein antibody; SKATe6055PtGA: patient’s global assessment; PGA: physician’s global assessment; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; HAQ: Health Assessment Questionnaire; csDMARD: conventional synthetic disease-modifying antirheumatic drug; bDMARD: biological DMARD.